Overview

Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).

Phase:

PHASE3

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd

Collaborator:

Deciphera Pharmaceuticals, LLC

Treatments:

Rituximab
Temozolomide
tirabrutinib